[go: up one dir, main page]

MA26936A1 - Derives de 3-indolyl-4 phenyl-1h-pyrrole-2,5-dione en tant qu'inhibiteurs de glycogene synthase kinase-3 beta - Google Patents

Derives de 3-indolyl-4 phenyl-1h-pyrrole-2,5-dione en tant qu'inhibiteurs de glycogene synthase kinase-3 beta

Info

Publication number
MA26936A1
MA26936A1 MA27013A MA27013A MA26936A1 MA 26936 A1 MA26936 A1 MA 26936A1 MA 27013 A MA27013 A MA 27013A MA 27013 A MA27013 A MA 27013A MA 26936 A1 MA26936 A1 MA 26936A1
Authority
MA
Morocco
Prior art keywords
glycogene
indolyl
pyrrole
phenyl
synthase kinase
Prior art date
Application number
MA27013A
Other languages
English (en)
Inventor
Leyi Gong
Gary Allen Peltz
Andrew Grupe
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26936A1 publication Critical patent/MA26936A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA27013A 2000-07-27 2003-01-24 Derives de 3-indolyl-4 phenyl-1h-pyrrole-2,5-dione en tant qu'inhibiteurs de glycogene synthase kinase-3 beta MA26936A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22105800P 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
MA26936A1 true MA26936A1 (fr) 2004-12-20

Family

ID=22826151

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27013A MA26936A1 (fr) 2000-07-27 2003-01-24 Derives de 3-indolyl-4 phenyl-1h-pyrrole-2,5-dione en tant qu'inhibiteurs de glycogene synthase kinase-3 beta

Country Status (31)

Country Link
US (2) US6479490B2 (fr)
EP (1) EP1307447B1 (fr)
JP (1) JP3984157B2 (fr)
KR (1) KR20030017655A (fr)
CN (1) CN1185229C (fr)
AR (1) AR033989A1 (fr)
AT (1) ATE284885T1 (fr)
AU (1) AU2001293702A1 (fr)
BR (1) BR0112965A (fr)
CA (1) CA2417277A1 (fr)
CZ (1) CZ2003555A3 (fr)
DE (1) DE60107857T2 (fr)
EC (1) ECSP034452A (fr)
ES (1) ES2233691T3 (fr)
GT (1) GT200100151A (fr)
HR (1) HRP20030030A2 (fr)
HU (1) HUP0301431A2 (fr)
IL (1) IL153851A0 (fr)
JO (1) JO2293B1 (fr)
MA (1) MA26936A1 (fr)
MX (1) MXPA03000695A (fr)
NO (1) NO20030328D0 (fr)
NZ (1) NZ523462A (fr)
PA (1) PA8523001A1 (fr)
PE (1) PE20020338A1 (fr)
PL (1) PL366701A1 (fr)
RU (1) RU2003104796A (fr)
UY (1) UY26857A1 (fr)
WO (1) WO2002010158A2 (fr)
YU (1) YU4403A (fr)
ZA (1) ZA200300216B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6593600A (en) * 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
EA200300442A1 (ru) * 2000-10-02 2003-10-30 Редди Ю Эс Терапьютикс, Инк. Способы и композиции для лечения воспалительных заболеваний
RU2329263C2 (ru) * 2000-11-07 2008-07-20 Новартис Аг Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
MXPA04002438A (es) * 2001-09-24 2004-06-29 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de pirroll para el tratamiento de la obesidad.
CN100409840C (zh) * 2002-01-10 2008-08-13 霍夫曼-拉罗奇有限公司 GSK-3β抑制剂在制备增加骨生成的药物中的应用
JP4414232B2 (ja) 2002-03-05 2010-02-10 イーライ リリー アンド カンパニー キナーゼ阻害物質
DE60315270T2 (de) 2002-03-08 2008-04-17 Eli Lilly And Co., Indianapolis Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
AR039209A1 (es) * 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
CN1671694A (zh) 2002-06-05 2005-09-21 詹森药业有限公司 作为激酶抑制剂的二吲哚基－顺丁烯二酰亚胺衍生物
AU2003240517A1 (en) 2002-06-05 2003-12-22 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
US7250444B2 (en) * 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
US7109436B2 (en) * 2003-08-29 2006-09-19 General Electric Company Laser shock peening target
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2005039549A1 (fr) * 2003-10-27 2005-05-06 Novartis Ag Derives d'indolyle-pyrroledione pour traiter des troubles neurologiques et vasculaires lies a la generation et/ou a l'agregation de beta-amyloide
UA85712C2 (ru) * 2004-05-12 2009-02-25 Байер Кропсайенс Аг Применение производного 3,4-замещенного малеимида для регулирования роста растений, композиция на ее основе и способ регулирования роста сельскохозяйственных растений
US8008320B2 (en) 2004-12-08 2011-08-30 Johannes Gutenberg-Universitatis 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
JP4747364B2 (ja) * 2005-04-04 2011-08-17 独立行政法人産業技術総合研究所 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
EP1928437A2 (fr) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
WO2007053596A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
CA2673368C (fr) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides en tant qu'inhibiteurs de gsk3 puissants pour troubles neurodegeneratifs
WO2008080824A1 (fr) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Cétales aromatiques sulfonés
KR20110031355A (ko) * 2008-06-25 2011-03-25 엔비보 파마슈티칼즈, 인코퍼레이티드 １,２―이치환된 헤테로사이클릭 화합물
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
EP2343291A1 (fr) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz Composés de 3-(indolyl)- ou 3-(azaindolyl)-4-arylmaléimide et leur utilisation dans le traitement de tumeurs
EP3045450B1 (fr) 2010-09-08 2018-02-07 Sumitomo Chemical Co., Ltd. Intermédiaires dans procédés de production de composés de pyridazinone
EP2474541A1 (fr) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Composés conjugués de 3-(indolyl)- et 3-(azaindolyl)-4-arylmaléimide et leur utilisation dans le traitement de tumeurs
KR20130034672A (ko) * 2011-09-28 2013-04-08 김동식 보텍스타입 열교환기
KR101440724B1 (ko) * 2013-03-29 2014-09-18 중앙대학교 산학협력단 글리코겐 신타아제 키나아제-3베타 억제물질을 유효성분으로 포함하는 난소과립세포종양의 예방 또는 치료용 약학적 조성물 및 건강기능성식품 조성물
WO2015155738A2 (fr) 2014-04-09 2015-10-15 Christopher Rudd Utilisation d'inhibiteurs ou d'activateurs de gsk -3 qui modulent l'expression de pd -1 ou de t-bet pour moduler l'immunité due aux lymphocytes t
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3187495A1 (fr) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz Composés de 3-(5-fluoroindolyl)-4-arylmaléimide et leur utilisation dans le traitement de tumeurs
WO2018132636A1 (fr) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York LIGANDS DE GLYCOGÈNE SYNTHASE KINASE-3β À BASE DE [18F]MALÉIMIDE POUR IMAGERIE PAR TOMOGRAPHIE PAR ÉMISSION DE POSITRONS ET PROCÉDÉ DE RADIOSYNTHÈSE
CN112538458B (zh) 2020-11-26 2025-10-31 北京孟眸生物科技有限公司 用于重编程细胞的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
CA2116460A1 (fr) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Agents prophylactiques ou therapeutiques pour la maladie d'alzheimer, methode de depistage de la maladie d'alzheimer et tau-proteine kinase i extraite d'un organisme humain
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
EP0868195A2 (fr) 1995-12-20 1998-10-07 Medical Research Council Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques
EP1019043A4 (fr) 1996-05-07 2003-07-30 Univ Pennsylvania Inhibiteurs de glycogene synthetase kinase-3 et procedes d'identification et d'utilisation de ces inhibiteurs
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
HK1038564A1 (zh) * 1998-10-08 2002-03-22 Smithkline Beecham Plc 用作糖原合酶激酶-3抑制劑的吡咯-2，5-二酮
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
UY26857A1 (es) 2002-01-31
WO2002010158A2 (fr) 2002-02-07
CN1444581A (zh) 2003-09-24
JP3984157B2 (ja) 2007-10-03
CN1185229C (zh) 2005-01-19
ATE284885T1 (de) 2005-01-15
PA8523001A1 (es) 2002-10-24
HUP0301431A2 (hu) 2003-08-28
HK1058670A1 (en) 2004-05-28
US20020188018A1 (en) 2002-12-12
DE60107857D1 (de) 2005-01-20
JP2004505078A (ja) 2004-02-19
EP1307447A2 (fr) 2003-05-07
ES2233691T3 (es) 2005-06-16
NO20030328L (no) 2003-01-22
CA2417277A1 (fr) 2002-02-07
BR0112965A (pt) 2003-07-08
AR033989A1 (es) 2004-01-21
PL366701A1 (en) 2005-02-07
YU4403A (sh) 2006-05-25
KR20030017655A (ko) 2003-03-03
HRP20030030A2 (en) 2005-02-28
US20020052397A1 (en) 2002-05-02
ECSP034452A (es) 2003-03-10
NO20030328D0 (no) 2003-01-22
MXPA03000695A (es) 2003-06-04
AU2001293702A1 (en) 2002-02-13
ZA200300216B (en) 2004-04-08
EP1307447B1 (fr) 2004-12-15
NZ523462A (en) 2004-09-24
RU2003104796A (ru) 2004-08-20
US6479490B2 (en) 2002-11-12
JO2293B1 (en) 2005-09-12
CZ2003555A3 (en) 2004-03-17
PE20020338A1 (es) 2002-04-23
DE60107857T2 (de) 2005-12-08
IL153851A0 (en) 2003-07-31
GT200100151A (es) 2002-05-23
WO2002010158A3 (fr) 2002-05-16

Similar Documents

Publication Publication Date Title
MA26936A1 (fr) Derives de 3-indolyl-4 phenyl-1h-pyrrole-2,5-dione en tant qu'inhibiteurs de glycogene synthase kinase-3 beta
MA26782A1 (fr) Pyrazolobenzodiazepines en tant qu'inhibiteurs de cdk2.
MA26932A1 (fr) Derives d'imidazole.
DE60037345D1 (de) Pyrroloi2,3-d pyrimidinderivate enthaltende Zusammensetzungen
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
DZ3439A1 (fr) Derives de 2-aminocarbonyl-9h-purine
FR15C0086I2 (fr) Derives d'hydroxamate en tant qu'inhibiteurs de desacetylase
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
MA26832A1 (fr) Derives de benzodiazepine.
MA26831A1 (fr) Derives de benzodiazepine."
PT1276738E (pt) Derivados de 2-amino-3-(alquil)-pirimidona como inibidores de gsk3.beta.
DK1073647T3 (da) 12,13-cyclopropan epothilon-derivater
PT1177185E (pt) Derivados de 4, 5, 6, 7-tetra-hidroindazole como agentes antitumorais
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
TR200000520A3 (tr) 4-Fenil-piridin türevleri.
DZ3159A1 (fr) Derives de purine.
DE50011602D1 (de) Wässrige, pigmenthaltige Beschichtungsmittel
ATE360620T1 (de) Imidazolderivate
MA26794A1 (fr) Derives de 5-phenyl-pyrimidine.
BR0013417B1 (pt) composiÇço aquosa.
FR2810318B1 (fr) Derives de diamano-phenothiazine
ATE309220T1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate
DK1368299T3 (da) Substituerede C-cyclohexylmethylaminderivater
MA26793A1 (fr) Derives de 4-phenyl-pyrimidine.
MA27094A1 (fr) Derives triazolo-quinoline utiles en tant que ligands recepteurs d'adenosine.